Drug Effectiveness Debate
A significant discussion unfolds around the effectiveness of newly approved drugs, highlighting that the median survival benefit for cancer treatments is often just 2.1 months. While some drugs, like Glebec, have transformed life expectancy for certain cancers, many others fall short in providing substantial benefits. The conversation critiques the current system that allows drugs with marginal improvements to dominate the market, sidelining alternatives that may offer comparable efficacy without the same financial backing.In this clip
From this podcast
EconTalk
Vinay Prasad on Pharmaceuticals, the FDA, and the Death of Duty
Related Questions